RxDoctor Payments Data

Meagan Adamson

Family · Fairfax, VANPI 1790061091

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,402 of the $34,440 with a category attached, or 62.1%. 17 manufacturers reported payments, led by Biogen at 34.9% of the total. Reporting peaked in 2021 at $12,268 and has fallen 96.3% since, to $455 in 2025. Among family clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$34,440in general payments, 2019–2025

Across 118 payments — averaging $291.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$12K
  • Sanofi$9K
  • Genentech USA, Inc.$4K
  • Bristol Myers Squibb$3K
  • E.r. Squibb & Sons, L.L.C.$3K
  • TG Therapeutics, Inc.$3K
  • plus $1K from 11 others

What the payments were for

  • Consulting fees$10,61531%
  • Speaking & faculty fees$21,40262%
  • Food & beverage$2,4127%
  • Education$120%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,440 in reported general payments places this provider in the 95th percentile of 4,332 family providers in Virginia.

See all family providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
RebifInterferon Beta-1a/Albumin25$283,247
BetaseronInterferon Beta-1b22$205,337
Kesimpta PenOfatumumab17$165,556
GilenyaFingolimod Hcl12$126,680
Teriflunomide53$103,232
Dimethyl Fumarate20$59,061
GlatopaGlatiramer Acetate15$47,783
Dalfampridine ErDalfampridine34$16,939
Aimovig AutoinjectorErenumab-Aooe19$13,831
MyrbetriqMirabegron12$5,865
Baclofen99$4,391
Modafinil26$2,843
Pregabalin41$2,653
FingolimodFingolimod Hcl12$2,568
Gabapentin143$2,502

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
EMD Serono, Inc.Rebif$219$283,24725 claims
NovartisGilenya$617$126,68012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,332 family providers in Virginia.

Other family in Fairfax

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →